• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    5/9/24 8:06:31 AM ET
    $AADI
    $CNSP
    $CTMX
    $CVM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AADI alert in real time by email

    Gainers

    • Zai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings report came out yesterday.
    • ZimVie (NASDAQ:ZIMV) shares moved upwards by 20.28% to $18.5. The market value of their outstanding shares is at $503.5 million. The company's, Q1 earnings came out yesterday.
    • Aadi Bioscience (NASDAQ:AADI) shares moved upwards by 16.84% to $2.15. The company's market cap stands at $52.7 million. As per the press release, Q1 earnings came out yesterday.
    • CEL-SCI (AMEX:CVM) shares moved upwards by 14.38% to $1.59. The company's market cap stands at $85.8 million.
    • Tarsus Pharmaceuticals (NASDAQ:TARS) shares moved upwards by 13.94% to $42.56. The market value of their outstanding shares is at $1.6 billion. As per the press release, Q1 earnings came out yesterday.
    • Embecta (NASDAQ:EMBC) shares rose 13.33% to $11.64. The company's market cap stands at $670.2 million. The company's, Q2 earnings came out today.

    Losers

    • Tivic Health Systems (NASDAQ:TIVC) shares declined by 35.8% to $0.86 during Thursday's pre-market session. The company's market cap stands at $1.2 million.
    • CytomX Therapeutics (NASDAQ:CTMX) shares declined by 30.32% to $2.92. The market value of their outstanding shares is at $198.9 million. As per the press release, Q1 earnings came out yesterday.
    • CNS Pharma (NASDAQ:CNSP) shares fell 13.84% to $0.21. The market value of their outstanding shares is at $2.1 million.
    • Ironwood Pharmaceuticals (NASDAQ:IRWD) shares decreased by 12.44% to $7.11. The market value of their outstanding shares is at $1.1 billion. As per the news, the Q1 earnings report came out today.
    • Syra Health (NASDAQ:SYRA) stock declined by 11.22% to $1.9. The company's market cap stands at $12.5 million. The company's, Q1 earnings came out today.
    • Exact Sciences (NASDAQ:EXAS) stock fell 10.56% to $53.2. The market value of their outstanding shares is at $9.7 billion. As per the news, the Q1 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AADI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AADI
    $CNSP
    $CTMX
    $CVM

    CompanyDatePrice TargetRatingAnalyst
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    Exact Sciences Corporation
    $EXAS
    1/20/2026$105.00Outperform → Neutral
    Mizuho
    Exact Sciences Corporation
    $EXAS
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    Ironwood Pharmaceuticals Inc.
    $IRWD
    1/5/2026$8.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Tarsus Pharmaceuticals Inc.
    $TARS
    12/9/2025$100.00Overweight
    Barclays
    Tarsus Pharmaceuticals Inc.
    $TARS
    11/20/2025$100.00Outperform
    Mizuho
    CytomX Therapeutics Inc.
    $CTMX
    9/22/2025$6.00Overweight
    Cantor Fitzgerald
    CytomX Therapeutics Inc.
    $CTMX
    9/17/2025$3.50Overweight
    Barclays
    More analyst ratings

    $AADI
    $CNSP
    $CTMX
    $CVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer John Minardo sold $136,177 worth of shares (36,492 units at $3.73), decreasing direct ownership by 9% to 363,886 units (SEC Form 4)

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    2/25/26 4:05:22 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, CMO, Head-Res&Drug Shetzline Michael sold $59,322 worth of shares (15,570 units at $3.81), decreasing direct ownership by 6% to 521,425 units (SEC Form 4)

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    2/25/26 4:05:17 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Mccourt Thomas A sold $739,929 worth of shares (198,283 units at $3.73), decreasing direct ownership by 12% to 1,489,002 units (SEC Form 4)

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    2/25/26 4:05:07 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $CNSP
    $CTMX
    $CVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on CytomX Therapeutics with a new price target

    Guggenheim initiated coverage of CytomX Therapeutics with a rating of Buy and set a new price target of $10.00

    1/20/26 9:23:09 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exact Sciences downgraded by Mizuho with a new price target

    Mizuho downgraded Exact Sciences from Outperform to Neutral and set a new price target of $105.00

    1/20/26 9:08:04 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Exact Sciences from Outperform to In-line and set a new price target of $105.00

    1/5/26 8:47:19 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $AADI
    $CNSP
    $CTMX
    $CVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/26/26 8:23:27 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kersten Geert R bought $49,998 worth of shares (8,389 units at $5.96), increasing direct ownership by 11% to 81,794 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    12/5/25 8:48:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Smiley Joshua L bought $289,100 worth of American Depositary Shares (10,000 units at $28.91), increasing direct ownership by 13% to 86,604 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    9/12/25 4:32:44 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $CNSP
    $CTMX
    $CVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tarsus to Participate in Upcoming Investor Conferences

    IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, at 11:30 a.m. PT / 2:30 p.m. ET.Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11th, at 9:30 a.m. PT / 12:30 p.m. ET. Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science

    2/26/26 4:30:00 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

    – Total revenues grew 17% y-o-y to $127.6 million for the fourth quarter of 2025 and 15% y-o-y to $460.2 million for the full-year 2025 – Zocilurtatug pelitecan (zoci) on track to become Zai Lab's first global oncology launch, with three registration-enabling studies across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026 – Advancing a differentiated global pipeline, including ZL-1503 (IL-13/IL-31Rα), ZL-6201 (LRRC15 ADC), ZL-1222 (PD-1/IL-12) and ZL-1311 (MUC17/CD3 TCE) – Key regional programs continue to advance, with KarXT approved in China and commercial launch preparations underway; pivotal data readouts for povetacicept in IgAN and elegrobart in TED expected in 2026

    2/26/26 7:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

    – LINZESS® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year – – 2025 Ironwood revenue of $296 million, GAAP net income of $24 million and adjusted EBITDA of $138 million – – Continue to expect full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million – – Key elements of confirmatory Phase 3 clinical trial design of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) have been finalized with site initiations expected to begin in the second quarter of 2026 – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and comm

    2/25/26 7:05:00 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $CNSP
    $CTMX
    $CVM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

    Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:35:13 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for issued to TARSUS PHARMACEUTICALS, INC.

    Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:35:13 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

    Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:29:16 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AADI
    $CNSP
    $CTMX
    $CVM
    SEC Filings

    View All

    SEC Form 10-K filed by Ironwood Pharmaceuticals Inc.

    10-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

    2/26/26 4:09:02 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Zai Lab Limited

    10-K - Zai Lab Ltd (0001704292) (Filer)

    2/26/26 7:08:13 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Zai Lab Ltd (0001704292) (Filer)

    2/26/26 7:04:12 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $CNSP
    $CTMX
    $CVM
    Leadership Updates

    Live Leadership Updates

    View All

    Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

    IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. "David is one of the most accomplished leaders in eye care, with a strong track record of translating innovation into global impact," said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. "His experience building some of the most successful franchises in our industry will be invaluable as we scale XDEMVY, advance our pipeline and position Tarsus for sustained growth. We are honored

    2/18/26 8:30:00 AM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $AADI
    $CNSP
    $CTMX
    $CVM
    Financials

    Live finance-specific insights

    View All

    Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

    – Total revenues grew 17% y-o-y to $127.6 million for the fourth quarter of 2025 and 15% y-o-y to $460.2 million for the full-year 2025 – Zocilurtatug pelitecan (zoci) on track to become Zai Lab's first global oncology launch, with three registration-enabling studies across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026 – Advancing a differentiated global pipeline, including ZL-1503 (IL-13/IL-31Rα), ZL-6201 (LRRC15 ADC), ZL-1222 (PD-1/IL-12) and ZL-1311 (MUC17/CD3 TCE) – Key regional programs continue to advance, with KarXT approved in China and commercial launch preparations underway; pivotal data readouts for povetacicept in IgAN and elegrobart in TED expected in 2026

    2/26/26 7:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

    – LINZESS® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year – – 2025 Ironwood revenue of $296 million, GAAP net income of $24 million and adjusted EBITDA of $138 million – – Continue to expect full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million – – Key elements of confirmatory Phase 3 clinical trial design of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) have been finalized with site initiations expected to begin in the second quarter of 2026 – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and comm

    2/25/26 7:05:00 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

    Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference call today, February 23, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced financial results for the fourth quarter and full-year ended December 31, 2025, and recent business achievements.

    2/23/26 4:05:00 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AADI
    $CNSP
    $CTMX
    $CVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

    SC 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

    11/14/24 4:41:12 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tarsus Pharmaceuticals Inc.

    SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

    11/14/24 4:35:55 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:26:32 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care